Taysha Gene Therapies, Inc. (TSHA)
4.005
-0.06
(-1.35%)
USD |
NASDAQ |
Nov 17, 16:00
4.005
0.00 (0.00%)
After-Hours: 20:00
Taysha Gene Therapies Enterprise Value : 954.90M for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 954.90M |
| November 13, 2026 | 967.94M |
| November 12, 2026 | 1.004B |
| November 11, 2026 | 1.027B |
| November 10, 2026 | 1.025B |
| November 09, 2026 | 1.056B |
| November 06, 2026 | 1.043B |
| November 05, 2026 | 964.68M |
| November 04, 2026 | 1.053B |
| November 03, 2026 | 964.68M |
| November 02, 2026 | 935.35M |
| October 30, 2026 | 977.72M |
| October 29, 2026 | 1.007B |
| October 28, 2026 | 1.010B |
| October 27, 2026 | 1.017B |
| October 26, 2026 | 938.61M |
| October 23, 2026 | 922.32M |
| October 22, 2026 | 936.98M |
| October 21, 2026 | 974.46M |
| October 20, 2026 | 971.20M |
| October 19, 2026 | 915.80M |
| October 16, 2026 | 811.51M |
| October 15, 2026 | 847.36M |
| October 14, 2026 | 775.67M |
| October 13, 2026 | 798.48M |
| Date | Value |
|---|---|
| October 12, 2026 | 980.97M |
| October 09, 2026 | 1.095B |
| October 08, 2026 | 1.075B |
| October 07, 2026 | 1.075B |
| October 06, 2026 | 1.062B |
| October 05, 2026 | 1.095B |
| October 02, 2026 | 1.141B |
| October 01, 2026 | 1.177B |
| September 30, 2026 | 1.219B |
| September 29, 2026 | 1.225B |
| September 28, 2026 | 1.225B |
| September 25, 2026 | 1.121B |
| September 24, 2026 | 1.160B |
| September 23, 2026 | 1.199B |
| September 22, 2026 | 1.280B |
| September 21, 2026 | 1.241B |
| September 18, 2026 | 1.234B |
| September 17, 2026 | 1.280B |
| September 16, 2026 | 1.251B |
| September 15, 2026 | 1.248B |
| September 14, 2026 | 1.231B |
| September 11, 2026 | 1.234B |
| September 10, 2026 | 1.280B |
| September 09, 2026 | 1.339B |
| September 08, 2026 | 1.384B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Imunon, Inc. | 6.587M |
| Altimmune, Inc. | 74.58M |
| Agenus, Inc. | 468.04M |
| Amgen, Inc. | 290.89B |
| Anika Therapeutics, Inc. | 154.24M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -39.13M |
| Total Expenses (Quarterly) | 39.13M |
| EPS Diluted (Quarterly) | -0.0964 |
| Earnings Yield | -10.89% |
| Normalized Earnings Yield | -10.55 |